Company: INMB
Filing Date: 2025-04-21
Form Type: DEF 14A
Source: 0001213900-25-033742
Chunk: 38

Company: Inmune Bio, Inc.
Filing Date: 2025-04-21
Form: DEF 14A
Chunk 38
---
 —            |     | 119,494 |
| Scott Juda, J.D.      |     | 2024 |     |    45,000 |     | —      |     | 248,598 |     | —            |     | 293,598 |
| Marcia Allen          |     | 2024 |     |    45,000 |     | —      |     | 248,598 |     | —            |     | 293,598 |

____________ (1)This column shows the grant date fair value of awards computed in accordance with stock -basedcompensation accounting rules Accounting Standards Codification Topic 718. (2)Resigned from the Board of Directors on July 5, 2024.

29 TRANSACTIONS WITH RELATED PERSONS The following is a description of the transactions and series of similar transactions for the year ended December 31, 2024, that the Company was a participant or will be a participant, in which: •transactions in which the amount involved exceeds the lesser of $120,000 or one percent of the average of the smaller reporting company’s total assets at year -endfor the last two completed fiscal years; and •any of the Company’s directors, executive officers, holders of more than 5% of our capital stock (which are referred to as “5% stockholders”) or any member of their immediate family had or will have a direct or indirect material interest, other than compensation arrangements with directors and executive officers. UCL During the year ended December 31, 2024, the Company paid UCL $321,000 for research and development services provided to the Company. UCL is a wholly owned subsidiary of the University of London. The Company’s Chief Scientific and Manufacturing Officer is a professor at the University of London. AmplifyBio During the years ended December 31, 2024, the Company paid AmplifyBio $384,000 to perform certain research and development services provided to the Company. The CEO of AmplifyBio is on the Board of Directors of the Company. April 2024 Registered Direct Offering On April 19, 2024, the Company entered into securities purchase agreements with investors whereby the Company sold 571,592 shares of the Company’s common stock and warrants to purchase an additional 571,592 shares of the Company’s common stock in a registered direct offering in exchange for gross proceeds of approximately $4.8 million (net proceeds of approximately $4.5 million). Directors and officers that participated in